0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multifocal Analysis of Acute Pain After Third Molar Removal

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: To analyze the pain modulation capacity profile in a Brazilian population, the relationship between opioid receptor ( OPRM1) and Catechol-O-methyltransferase ( COMT) 1polymorphisms and pain modulation capacity was determined through preoperative pain modulation tests and acute postoperative pain control evaluation, swelling, and trismus in 200 volunteers undergoing lower third molar removal.

          Methods: Psychologic and clinical parameters were measured. Patient DNA was sequenced for single nucleotide polymorphisms in OPRM1 and COMT, and the salivary concentration of interleukin (IL)-2 (IL)-6, interferon (IFN)-γ and tumor necrosis factor (TNF)-α was evaluated. Primary outcomes were the influence of all predictors on the fluctuation of pain intensity using a visual analogue scale (VAS), and swelling and trismus on the 2nd and 7th postoperative days. Preoperative pain modulation capacity (CPM), pain catastrophizing scale (PCS), body mass index (BMI), and surgery duration and difficulty were evaluated.

          Results: Salivary concentration of IFN-γ and IL-2 as well as the duration of surgery influenced the fluctuation of postoperative pain in the VAS, and in the sum of the differences in pain intensity test at 8, 48, and 96 h. BMI influenced swelling, while both BMI and COMT haplotype influenced trismus on the 2nd postoperative day.

          Conclusion: Polymorphisms in COMT, salivary concentrations of IL-2 and IFN-γ, BMI, and duration of surgery were predictors for pain fluctuation, swelling, and trismus on the 2nd day after lower third molar extraction. This therapy was effective in controlling inflammatory symptomatology after lower third molar extraction and ibuprofen was well tolerated by patients.

          Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03169127.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: not found
          • Article: not found

          The Pain Catastrophizing Scale: Development and validation.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cross-cultural adaptation and validation of the Brazilian Portuguese version of the pain catastrophizing scale.

            Catastrophizing is a maladaptive response to pain and is one of the factors that contribute to the chronicity of some pain syndromes. The Pain Catastrophizing Scale (PCS) assists both treatment planning and outcome assessment. Its use is limited in Portuguese-speaking countries because of the lack of a validated translated version. We conducted the validation of the Brazilian Portuguese (BP)-PCS and explored its psychometric properties. This study reports the internal consistency, factor structure, and its capability to discriminate pain reported by patients with specific chronic pain conditions. Three hundred eighty-four patients, 317 women (82.55%), aged 18-79 years with chronic nonmalignant pain attending an outpatient multidisciplinary pain center participated in this cross-sectional study. The instruments were the BP-PCS, pain intensity, pain interference in functional capacity, and a sociodemographic questionnaire. One subsample with chronic tensional headache (CTH) according to the criteria of the International Headache Society (N = 19), and another with a diagnosis of fibromyalgia according to the American College of Rheumatology criteria (N = 50) were selected to assess the discriminative properties of BP-PCS. We observed good internal consistency (Cronbach's α values of 0.91 for the total BP-PCS, and 0.93 [helplessness], 0.88 [magnification], and 0.86 [rumination] for the respective subdomains). The item-total correlation coefficients ranged from 0.91 to 0.94. Confirmatory factor analysis (CFA) supported the three factors structure, with the comparative fit index = 0.98, root mean square error of approximation = 0.09, and normed fit index = 0.98. Significant correlations were found for pain intensity, pain interference, and patient's mood (correlation coefficients ranged from 0.48 to 0.66, P < 0.01). No significant gender difference was observed for BP-PCS scores. When comparing scores of BP-PCS scale and subscales between the selected control group (patients with pain scores on visual analog scale equal or lower than 40 mm in the most part of the day in the last 6 months) and patients with fibromyalgia or CTH, we observed lower scores for the former group. Our findings support the validity and reliability of the BP-PCS. The scale showed satisfactory psychometric properties. CFA provides support for the three-factor structure reported in previous studies. This factor structure presented good discriminative properties to identify catastrophizers who present with mild chronic pain, fibromyalgia, and CTH. The BP-PCS is a valuable tool for use in scientific studies and in the clinical setting in patients with chronic pain in Brazilian Portuguese-speaking countries. Wiley Periodicals, Inc.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Single-nucleotide polymorphism in the human mu opioid receptor gene alters  -endorphin binding and activity: Possible implications for opiate addiction

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                15 April 2021
                2021
                : 12
                : 643874
                Affiliations
                [ 1 ]Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil
                [ 2 ]Department of Biosciences, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil
                [ 3 ]Kailos Genetics Inc., HudsonAlpha Institute for Biotechnology, Huntsville, AL, United States
                [ 4 ]HudsonAlpha Institute for Biotechnology, Huntsville, AL, United States
                Author notes

                Edited by: Katherine N. Theken, University of Pennsylvania, United States

                Reviewed by: Lucia Taja-Chayeb, National Institute of Cancerology (INCAN), Mexico

                Elliot Hersh, University of Pennsylvania, United States

                *Correspondence: Carlos Ferreira Santos, cfsantos@ 123456fob.usp.br

                This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology

                Article
                643874
                10.3389/fphar.2021.643874
                8082138
                6bd50aed-9806-4c1b-b010-0c5004e23d72
                Copyright © 2021 Weckwerth, Dionísio, Costa, Zupelari-Gonçalves, Oliveira, Torres, Bonjardim, Faria, Calvo, Moore, Absher and Santos.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 December 2020
                : 05 March 2021
                Funding
                Funded by: Fundação de Amparo à Pesquisa Do Estado de São Paulo 10.13039/501100001807
                Award ID: 2016/12671-5 2018/04157-5
                Funded by: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 10.13039/501100002322
                Categories
                Pharmacology
                Clinical Trial

                Pharmacology & Pharmaceutical medicine
                catechol o-methyltransferase (comt),opioid receptor,pain,nsaids (non-steroidal anti-inflammatory drugs),polymorphisms

                Comments

                Comment on this article